Adial Pharmaceuticals Inc (ADIL) Actualités

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan’s 2023 North American...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

CHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW...

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 8-K/A - Current report: [Amend]

Form NT 10-Q/A - Notification of inability to timely file Form 10-Q or 10-QSB: [Amend]

Form D - Notice of Exempt Offering of Securities

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

CHARLOTTESVILLE, Va., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial”...

Form 8-K - Current report

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or...

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or...

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

CHARLOTTESVILLE, Va., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW...